Cited by 600Diabetes and associated disordersDiabetes Management and ResearchDiabetes, Cardiovascular Risks, and Lipoproteins

Risk of diabetes-associated diseases in subgroups of patients with recent-onset diabetes: a 5-year follow-up study

Zaharia, Oana P, Strassburger, Klaus, Strom, Alexander, Bönhof, Gidon J, Karusheva, Yanislava, Antoniou, Sofia, Bódis, Kálmán, Markgraf, Daniel F +36 more·2019·The Lancet Diabetes & Endocrinology

Abstract

Background Cluster analyses have proposed different diabetes phenotypes using age, BMI, glycaemia, homoeostasis model estimates, and islet autoantibodies. We tested whether comprehensive phenotyping validates and further characterises these clusters at diagnosis and whether relevant diabetes-related complications differ among these clusters, during 5-years of follow-up.Methods Patients with newly diagnosed type 1 or type 2 diabetes in the German Diabetes Study underwent comprehensive phenotyping and assessment of laboratory variables. Insulin sensitivity was assessed using hyperinsulinaemic-euglycaemic clamps, hepatocellular lipid content using magnetic resonance spectroscopy, hepatic fibrosis using non-invasive scores, and peripheral and autonomic neuropathy using functional and clinical criteria. Patients were reassessed after 5 years. The German Diabetes Study is registered with ClinicalTrials.gov, number NCT01055093, and is ongoing.Findings 1105 patients were classified at baseline into five clusters, with 386 (35%) assigned to mild age-related diabetes (MARD), 323 (29%) to mild obesity-related diabetes (MOD), 247 (22%) to severe autoimmune diabetes (SAID), 121 (11%) to severe insulin-resistant diabetes (SIRD), and 28 (3%) to severe insulin-deficient diabetes (SIDD). At 5-year follow-up, 367 patients were reassessed, 128 (35%) with MARD, 106 (29%) with MOD, 88 (24%) with SAID, 35 (10%) with SIRD, and ten (3%) with SIDD. Whole-body insulin sensitivity was lowest in patients with SIRD at baseline (mean 4·3 mg/kg per min [SD 2·0]) compared with those with SAID (8·4 mg/kg per min [3·2]; p<0·0001), MARD (7·5 mg/kg per min [2·5]; p<0·0001), MOD (6·6 mg/kg per min [2·6]; p=0·0011), and SIDD (5·5 mg/kg per min [2·4]; p=0·0035). The fasting adipose-tissue insulin resistance index at baseline was highest in patients with SIRD (median 15·6 [IQR 9·3-20·9]) and MOD (11·6 [7·4-17·9]) compared with those with MARD (6·0 [3·9-10·3]; both p<0·0001) and SAID (6·0 [3·0-9·5]; both p<0·0001). In patients with newly diagnosed diabetes, hepatocellular lipid content was highest at baseline in patients assigned to the SIRD cluster (median 19% [IQR 11-22]) compared with all other clusters (7% [2-15] for MOD, p=0·00052; 5% [2-11] for MARD, p<0·0001; 2% [0-13] for SIDD, p=0·0083; and 1% [0-3] for SAID, p<0·0001), even after adjustments for baseline medication. Accordingly, hepatic fibrosis at 5-year follow-up was more prevalent in patients with SIRD (n=7 [26%]) than in patients with SAID (n=5 [7%], p=0·0011), MARD (n=12 [12%], p=0·012), MOD (n=13 [15%], p=0·050), and SIDD (n=0 [0%], p value not available). Confirmed diabetic sensorimotor polyneuropathy was more prevalent at baseline in patients with SIDD (n=9 [36%]) compared with patients with SAID (n=10 [5%], p<0·0001), MARD (n=39 [15%], p=0·00066), MOD (n=26 [11%], p<0·0001), and SIRD (n=10 [17%], p<0·0001).Interpretation Cluster analysis can characterise cohorts with different degrees of whole-body and adipose-tissue insulin resistance. Specific diabetes clusters show different prevalence of diabetes complications at early stages of non-alcoholic fatty liver disease and diabetic neuropathy. These findings could help improve targeted prevention and treatment and enable precision medicine for diabetes and its comorbidities.Funding German Diabetes Center, German Federal Ministry of Health, Ministry of Culture and Science of the state of North Rhine-Westphalia, German Federal Ministry of Education and Research, German Diabetes Association, German Center for Diabetes Research, Research Network SFB 1116 of the German Research Foundation, and Schmutzler Stiftung.

Integrity signals

Registry

Crossref · 10.1016/s2213-8587(19)30187-1

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The citation lists haven’t been fetched yet

References 32 · Cited by 600

Authors
Zaharia, O. P., Strassburger, K., Strom, A., Bönhof, G. J., Karusheva, Y., Antoniou, S., Bódis, K., Markgraf, D. F., Burkart, V., Müssig, K., Hwang, J.-H., Asplund, O., Groop, L., Ahlqvist, E., Seissler, J., Nawroth, P., Kopf, S., Schmid, S. M., Stumvoll, M., Pfeiffer, A. F. H., Kabisch, S., Tselmin, S., Häring, H. U., Ziegler, D., Kuss, O., Szendroedi, J., Roden, M., Belgardt, B.-F., Buyken, A., Eckel, J., Geerling, G., Al-Hasani, H., Herder, C., Hwang, J.-H., Icks, A., Kotzka, J., Kuss, O., Lammert, E., Markgraf, D., Müssig, K., Rathmann, W., Roden, M., Szendroedi, J., & Ziegler, D.
Affiliations
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Lund University (SE)
  • Helmholtz Munich (DE)
  • University Hospital Heidelberg (DE)
  • German Center for Diabetes Research (DE)
  • Universitätsklinikum Tübingen (DE)
Venue
The Lancet Diabetes & Endocrinology
Publisher
Elsevier BV
Published
2019-09
Volume
7
Issue
9
Pages
684-694
ISSN
2213-8587 (ISSN-L)
OpenAlex
W2964211103
Cited by
600
References
32
Citations by year
2026: 63 · 2025: 93 · 2024: 98 · 2023: 90 · 2022: 92 · 2021: 87 · 2020: 62 · 2019: 13 · 2018: 1 · 2017: 1
FWCI
38.27
Type
journal article
Language
en
Open access
closed
Locations
  • The Lancet Diabetes & Endocrinology (publishedVersion)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Site cant be reached (submittedVersion)
  • PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
Funders
  • Deutsche Forschungsgemeinschaft
  • Bundesministerium für Bildung und Forschung (SFB 1116)
  • Schmutzler Stiftung
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
diabetes phenotypes, clustering, type 1 diabetes, type 2 diabetes, recent-onset diabetes, insulin resistance, insulin sensitivity, hepatic steatosis, liver fibrosis, diabetes complications, diabetic nephropathy, diabetic retinopathy, diabetic neuropathy, autonomic neuropathy, islet autoantibodies, HOMA-IR, German Diabetes Study, longitudinal follow-up
MeSH terms
Adult, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Germany, Humans, Insulin Resistance, Male, Gas Chromatography-Mass Spectrometry, Middle Aged, Phenotype, Time Factors, Glucose Clamp Technique, Cluster Analysis, Diabetes Complications

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review